A phase I study evaluating the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
Latest Information Update: 01 Nov 2017
At a glance
- Drugs DTS 201 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Diatos
- 19 Oct 2017 Results published in the European Journal of Cancer
- 28 Mar 2006 New trial record.